Olfactory threshold predicts treatment response in relapsing multiple sclerosis.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
09 2022
Historique:
pubmed: 15 3 2022
medline: 27 7 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS). We aimed to investigate OT for prediction of treatment response in RMS. In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models. Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44, OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.

Sections du résumé

BACKGROUND
Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS).
OBJECTIVE
We aimed to investigate OT for prediction of treatment response in RMS.
METHODS
In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models.
RESULTS
Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44,
CONCLUSIONS
OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.

Identifiants

pubmed: 35282741
doi: 10.1177/13524585221079744
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1541-1552

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Gabriel Bsteh (G)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Harald Hegen (H)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Klaus Berek (K)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Patrick Altmann (P)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Michael Auer (M)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Franziska Di Pauli (F)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Lukas Haider (L)

Department of Neuroradiology, Medical University of Vienna, Vienna, Austria.

Fritz Leutmezer (F)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Paulus Rommer (P)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Lisa-Maria Walchhofer (LM)

Department of Neuroradiology, Medical University of Innsbruck, Innsbruck, Austria.

Sebastian Wurth (S)

Department of Neurology, Medical University of Graz, Graz, Austria.

Anne Zinganell (A)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Florian Deisenhammer (F)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Thomas Berger (T)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH